Ποια είναι η τιμή για Xuanzhubio-b (2575)

Η τιμή για Xuanzhubio-b (2575) είναι $1.35

Ποια είναι η κεφαλαιοποίηση αγοράς για Xuanzhubio-b (2575)

Η κεφαλαιοποίηση αγοράς για Xuanzhubio-b (2575) είναι $700.36M

Xuanzhubio-b (2575) Τιμή και Κεφαλαιοποίηση Αγοράς

Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.

Η τιμή για 2575	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$10,162.93 $700.36M	NVDA	$5.264T	+751,495.87%
$9,076.74 $700.36M	AAPL	$4.701T	+671,166.78%
$8,064.86 $700.36M	GOOG	$4.177T	+596,333.97%
$7,370.24 $700.36M	MSFT	$3.817T	+544,963.64%
$5,534.03 $700.36M	AMZN	$2.866T	+409,166.92%

Η τιμή για 2575

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$10,162.93 $700.36M